Cupertino, CA, United States of America

Valery Antonenko

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2011

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Valery Antonenko: Innovator in P38 Inhibition

Introduction

Valery Antonenko is a prominent inventor based in Cupertino, California, known for her significant contributions to the field of medical science. With a focus on innovations that promote human health, she has made strides in developing compounds aimed at inhibiting p38, a critical protein involved in various inflammatory processes.

Latest Patents

One of Valery's noteworthy achievements includes her patent titled "Inhibitors of P38 and methods of using the same." This invention encompasses compounds that effectively inhibit the p38 protein, providing methods for doing so both in vivo and in vitro. Moreover, the patent presents groundbreaking approaches for treating conditions associated with p38 activity or cytokine activity, showcasing the potential impact of her work on therapeutic strategies.

Career Highlights

Valery currently works at Arqule, Inc., a biopharmaceutical company that specializes in developing targeted therapies for cancer and other diseases. Through her role, she has been at the forefront of innovative medical research, contributing to advancements that hold promise for improving patient outcomes.

Collaborations

Throughout her career, Valery has collaborated with esteemed colleagues such as Mark Anthony Ashwell and Syed M Ali. These partnerships illustrate the collaborative spirit within the scientific community, driving forward the boundaries of knowledge and innovation in healthcare.

Conclusion

Valery Antonenko’s contributions to the field of medical inventions are marked by her innovative approach to targeting the p38 pathway. Her patent exemplifies her dedication to addressing pressing health challenges through scientific discovery. As she continues to work at Arqule, Inc. and collaborate with other experts, her impact on healthcare and therapeutic development is poised to grow even further.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…